Scholarlink

<p>Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, with extremity and superficial trunk STS (eSTS) comprising the majority of cases. The management of localized eSTS requires a multidisciplinary approach to optimize oncologic and functional outcomes. This review outlines the natural history, diagnostic workup, and treatment principles for localized eSTS, emphasizing the role of histology-specific considerations in guiding management strategies. While surgery remains the mainstay of treatment, with the goal of achieving negative margins and preserving limb function, radiotherapy is frequently employed to reduce the risk of local recurrence. Systemic therapies, including chemotherapy and immunotherapy, are increasingly being explored in both the neoadjuvant and adjuvant settings. Recent evidence suggests that chemotherapy may provide a survival benefit in selected high-risk patients. Additionally, emerging data on immune checkpoint inhibitors indicate potential efficacy in specific histologic types and in combination with radiotherapy. Given the complexity of diagnosis and treatment, centralization of care in specialized sarcoma centers is critical to ensure optimal patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ASO Practice Guidelines Series: Soft Tissue Sarcoma of the Extremities and Superficial Trunk

  • 期刊论文

  • 发表日期：

    2025年9月10日

查看全文
  • Dario Callegaro,
  • Catherine Sarre Lazcano,
  • Kenneth Cardona

摘要

Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, with extremity and superficial trunk STS (eSTS) comprising the majority of cases. The management of localized eSTS requires a multidisciplinary approach to optimize oncologic and functional outcomes. This review outlines the natural history, diagnostic workup, and treatment principles for localized eSTS, emphasizing the role of histology-specific considerations in guiding management strategies. While surgery remains the mainstay of treatment, with the goal of achieving negative margins and preserving limb function, radiotherapy is frequently employed to reduce the risk of local recurrence. Systemic therapies, including chemotherapy and immunotherapy, are increasingly being explored in both the neoadjuvant and adjuvant settings. Recent evidence suggests that chemotherapy may provide a survival benefit in selected high-risk patients. Additionally, emerging data on immune checkpoint inhibitors indicate potential efficacy in specific histologic types and in combination with radiotherapy. Given the complexity of diagnosis and treatment, centralization of care in specialized sarcoma centers is critical to ensure optimal patient outcomes.